Last reviewed · How we verify
ASP7517
At a glance
| Generic name | ASP7517 |
|---|---|
| Sponsor | Astellas Pharma Global Development, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Chills
- Urticaria
- Anaemia
- Diarrhoea
- Mouth haemorrhage
- Nausea
- Nasopharyngitis
- Pharyngitis
- Arthralgia
- Dizziness
- Headache
- Haematuria
Key clinical trials
- Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen (PHASE1, PHASE2)
- A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |